Vifor Pharma : INVESTOR FACTSHEET

Investor Factsheet

About us

Vifor Pharma Group is a global pharmaceutical company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is the partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care.

P&L overview

In CHF million	FY 2021 FY 2020 Growth
Net sales	1'754.2	1'705.6	2.8%
Gross profit	1'152.9	1'100.8	4.7%
EBITDA	602.0	575.8	4.6%
Net profit1	265.4	237.6	11.7%
To VP shareholders	146.6	138.7	5.7%
To minorities	118.8	98.9	20.1%
Core EPS	6.05	4.99	21.2%
Average # of FTE	2'300	2'429	-5.3%

Balance sheet & cash flow overview

In CHF million	31.12.2021	31.12.2020
Operating cash flow	527.4
Investing cash flow	(48.8)
Financing cash flow	(210.9)
Exchange rate effects	(4.1)
Cash & cash equivalents	993.6	730.0
Financial liabilities	(539.8)	(539.5)
(Net debt) / Net cash	453.8	190.6
Equity ratio	77.8%	77.1%

EPS = earnings per share	VP = Vifor Pharma
FTE = full-time employees	1) from continuing operations
				Net sales split
Main commercial products			FY 2021, in CHF million
Name	Indication	Type		Others; 188.0
Ferinject®/Injectafer®	ID/IDA	Own product		Veltassa®;
Venofer®	ID/IDA	Own product		114.2	Ferinject®/Injectafer®;
Maltofer®	ID/IDA	Own product		Venofer®; 144.3	665.7
Mircera®	Anemia	In-licensed
Retacrit®	Anemia	In-licensed		Velphoro®; 179.2
Velphoro®	HP	Own product			Mircera®/Retacrit®;
Veltassa®	HK	Own product			462.6
ID = iron deficiency	HP = hyperphosphatemia
IDA = ID anemia	HK = hyperkaliemia

Other own and in-licensed products

Product	Company	Indication	Status	Geographies
ANG-3777	Angion Biomedica	CSA-AKI	P2 study	Worldwide ex-Greater China
TavneosTM	ChemoCentryx	ANCA-AV; C3G	Launched	Ex-US
INS-3001	Vifor Pharma	PAD1; AVS	P1 study	Worldwide
KorsuvaTM	Cara Therapeutics	Uremic Pruritus	Preparing to launch Worldwide ex-Japan & S. Korea
Rayaldee®	Opko Health	SHPT1	Launched	Selected geographies ex-US
SNF472	Vifor Pharma	CUA; PAD2	P3 study	Worldwide
Sparsentan	Travere Therapeutics	FSGS; IgAN	P3 studies	Europe, Australia & New Zealand
Vadadustat	Akebia Therapeutics	Dialysis3	Filed in US	US, selected dialysis providers1
Vamifeport	Vifor Pharma	BT; SCD	P2 studies	Worldwide

CSA-AKI = cardiac surgery-associated AKI ANCA-AV = anti-neutrophil cytoplasmic autoantibody-associated vasculitis

C3G = Complement 3 Glomerulopathy	PAD = peripheral artery disease AVS = aortic valve stenosis
SHPT = secondary hyperparathyroidism	CUA = calcific uremic arteriolopathy FSGS = focal segmental glomerulosclerosis

IgAN = IgA Nephropathy BT = beta-thalassemia SCD = sickle cell disease

1) non-dialysis chronic kidney disease (CKD) 2) dialysis CKD 3)Subject to certain conditions

© Vifor Pharma

Page 1 of 2

February 2022

Investor Factsheet

Group structure

VIFOR PHARMA GROUP

							55%1
	100%

1) Joint company with Fresenius Medical Care

History

1927 16 pharmacists establish a joint purchasing center, forming the basis of Galenica 1997 Galenica reinforces commitment to the development of Vifor Ltd. portfolio 2000 FDA approves Venofer® for IDA treatment in dialysis

2007 Ferinject® is approved in Europe

2010 Creation of the joint company Vifor Fresenius Medical Care Renal Pharma (VFMCRP)

2013 Injectafer® (US brand name of Ferinject®) and Velphoro® launched in the US

2015 Exclusive agreement with Roche for the commercialization of Mircera® in the US 2016 Acquisition of Relypsa, In-licensing of TavneosTM, Rayaldee® and Retacrit® 2017 IPO of Galenica Santé, Galenica Group renamed Vifor Pharma Group

2018 In-licensing of KorsuvaTM

2020 Extension of KorsuvaTM in-licensing agreement, in-licensing of ANG-3777 and OM Pharma divestment 2021 In-licensing of Sparsentan, acquisition of Sanifit Therapeutics and Inositec AG, CSL tender offer

Stock information

Total shares	65'000'000
Free float	~64%
Primary exchange	SIX Swiss Exchange
Ticker	VIFN SW
ISIN	CH0364749348

Significant shareholders1

Beneficial owner	Position
CSL Limited, Vifor Pharma AG	23.34%
JPMorgan Chase & Co.	6.93%
BlackRock, Inc.	5.61%

1) According to SIX disclosures as of 11.02.2022

Analyst coverage

Institution	Analyst	Institution	Analyst	Institution	Analyst
Baader Helvea	Leonildo Delgado	Kepler	Dariusz Ubik	R. Partners Urs Kunz
Berenberg	Diana Na	Mirabaud	Gianpaolo Chiriano	Stifel	Christian Glennie
Credit Suisse	Christoph Gretler	Morgan Stanley	Sarita Kapila	UBS	Laura Sutcliffe
Deutsche Bank	Emmanuel Papadakis	Octavian	Laura Pfeiffer-Rossi	ZKB	Laurent Flamme
J.P. Morgan	James Gordon	Oddo BHF	Daniel Wendorff

Board of Directors

Jacques Theurillat (Chairman) Prof. Hon. Dr. Michel Burnier Dr. Romeo Cerutti

Dr. Alexandre LeBeaut Dr. Sue Mahoney Åsa Riisberg

Kim Stratton

Further information

Laurent de Weck

Investor Relations & Treasury Senior Manager https://www.viforpharma.com/en/[e-mail]

Executive Committee (EC)

Abbas Hussain	Chief Executive Officer
Alexandros Sigalas	Acting Chief Financial Officer
Barbara Angehrn	Chief Business Officer
Hervé Gisserot	Chief Commercial Officer
Dr. Klaus Henning Jensen	Chief Medical Officer
Dr. Oliver P. Kronenberg	Group General Counsel
Michael Puri	Chief HR Officer
Dr. Christoph Springer	Chief Strategy Officer

Corporate events

26.04.2022 Annual General Meeting 04.08.2022 Half-year results 2022

© Vifor Pharma

Page 2 of 2

February 2022